

Table I. Allergens in cosmetic products

Type of product	Substance in most standard battery screening patch tests
Fragrances	Balsam of Peru, fragrance mix
Preservatives	Parabens, formaldehyde, quaternium-15, imidazolidiny urea, Kathon 6, Euxyl K400
Dyes	PPD
Rubber components	Thiuram/carba/mercapto mix
Metals	Nickel ¹⁰

All hair care products have the potential to cause ACD.

Declaration of conflict of interest

The authors declare no conflict of interest.

REFERENCES

1. Rietschel RL, Goossens A, Conde-Salazar L, Veien NK. *Atlas of Contact Dermatitis*. London: Informa Health Care, 1999: 2.
2. Tomar J, Jain VK, Aggarwal K, Dayal S, Gupta S. Contact allergies to cosmetics: testing with 52 cosmetic ingredients and personal products. *J Dermatol* 2005; **31**: 951-955.
3. Wolf R, Wolf D, Tuzun B, et al. Contact dermatitis to cosmetics. *Clin Dermatol* 2001; **19**: 502-515.
4. Krasteva M, Cottin M, Cristaudo A, et al. Sensitivity and specificity of the consumer open skin allergy test as a method of prediction of contact dermatitis to hair dyes. *Eur J Dermatol* 2005; **15**: 18-25.
5. Uter W, Lessmann H, Geier J, Schnuch A. Contact allergy to ingredients of hair cosmetics in female hairdressers and clients – an 8-year analysis of IVDK data. *Contact Dermatitis* 2003; **49**: 236-240.
6. Khumalo NP, Jessop S, Ehrlich R. Prevalence of cutaneous adverse effects of hair dressing. *Arch Dermatol* 2006; **142**: 377-383.
7. Raboobee N. Sensitisation from PPD in temporary henna tatoos and subsequent severe allergic contact dermatitis from hair dye. *Current Allergy & Clinical Immunology* 2004; **17**: 194-195.
8. Bolduc C, Shapiro J. Hair care products: waving, straightening, conditioning, and coloring. *Clin Dermatol* 2001; **19**: 431-436.
9. Cogen FC, Beezhold DH. Hair glue anaphylaxis: a hidden latex allergy. *Ann Allergy Asthma Immunol* 2002; **88**: 61-63.
10. Rycroft RJG, Menne T, Frosch PJ, Benezra J, eds. *Textbook of Contact Dermatitis*, 2nd ed. Berlin: Springer-Verlag, 1995: 182, 374.

PRODUCT NEWS

Long-chain polyunsaturated fatty acids influence the immune system of infants

Gottrand F. EA 3925, IFR 114, Faculty of Medicine and University of Lille 2, Lille, France. fgottrand@chru-lille.fr

Several events occur during the first months of life that allow the immune system to become competent and functional. The aim of this article is to review the rationale and evidence of an influence of (n-3) long-chain PUFA (LCPUFA) on the immune system of infants. The (n-3) LCPUFA exert their immunomodulatory activities at different levels. The (n-3) LCPUFA metabolites induce eicosanoid production, alter gene expression, and modify lipid raft composition, altering T-cell signalling; all contribute to immunological functional changes. However, the roles of these mechanisms and the types of T or other immunological cells involved remain unclear at present. Moreover, the effect of (n-3) LCPUFA on the immune system of infants may vary according to dose, time of exposure, and



profile of the immune system (T-helper, Th1/Th2). Most of the interventional studies in infancy have been performed for the prevention of allergy. They all confirmed influence on T-cell function and cytokine profiles, but clinically beneficial effects are more conflicting. Supplementation of the maternal diet in pregnancy or early childhood with (n-3) LCPUFA is potentially a noninvasive intervention strategy to prevent the development of allergy, infection, and possibly other immune-mediated diseases. However, any long-term *in vivo* effects on (n-3) LCPUFA early in life for immunomodulatory defence in infants and later on immune status and health remain to be assessed.

J Nutr 2008; 138(9): 1807S-1812S.

For more information please contact Nestlé Consumer Services on 0860 09 67 89

PRODUCT NEWS

NEW DESIGN FOR SYMBICORD

AstraZeneca is proud to introduce a new design for Symbicord boxes and packaging. The purpose of the packaging change is to standardise the colours and design globally, so that wherever in the world you may be, the Symbicord packaging will look the same.

In line with these changes, we are also keeping these colours for our promotional and educational material, so that the design is standardised throughout. The new look is bold, positive, professional and modern, with an emphasis on clinically relevant and clear information. The approach is future-focused, to reflect the constant innovation and challenging of conventions that is the basis of our approach to medicine at AstraZeneca.

Please note that the ingredients and doses of Symbicord will remain the same.

In conjunction with the new look, AstraZeneca intends to introduce user-friendly educational and support material to assist and support people with asthma.

The new material is aimed at providing the busy physician and his/her patients with the tools that they need so that people with asthma can take responsibility for their own asthma control.

S 3 Symbicord® Turbuhaler® 80:4,5 µg/dose (Inhaler), Reg No. 35/21.5.1/0404. Each delivered dose contains as active constituents: Budesonide 80 micrograms and formoterol fumarate dihydrate 4,5 micrograms.



S 3 Symbicord® Turbuhaler® 160:4,5 µg/dose (Inhaler), Reg No. 35/21.5.1/0405. Each delivered dose contains as active constituents: 160 micrograms and formoterol fumarate dihydrate 4,5 micrograms.

S 3 Symbicord® Turbuhaler® 320:9 µg/dose (Inhaler), Reg No. 38/21.5.1/0187. Each delivered dose contains as active constituents: Budesonide 320 micrograms and formoterol fumarate dihydrate 9 micrograms.

NAME AND BUSINESS ADDRESS OF THE HOLDER OF THE CERTIFICATE OF REGISTRATION:

AstraZeneca Pharmaceuticals (Pty) Limited, 5 Leeuwkop Road, Sunninghill, 2157, South Africa. Reg No. 92/05854/07. Tel: +27 11 797 6000. Fax: +27 11 797 6001. www.astrazeneca.co.za

The diagnostic value of IgE antibody measurements to peanut allergen components

Clinical background

Peanut food allergy is a major public health problem because of its severity and prevalence, which is estimated to be 0.5-1.8% depending on the population group studied. Peanut is the most common food to cause fatal and near-fatal food allergy.

Useful diagnostic tests for food allergy are *in vitro* serum food-specific IgE assays, skin-specific IgE determination, basophil activation tests and oral food challenges.

Currently the only way to assess a peanut sensitisation is the use of native peanut extracts. Because of variability of the raw material linked to its origin and conditions of production and storage, investigators are confronted with a lack of standardisation of the material used both for *in vitro* and *in vivo* testing. Production of recombinant allergens is a promising way to obtain biological material with consistent and standardised properties and will enable further characterisation of the peanut-allergic patient.

Phadia has released a number of new recombinant allergens for peanut.

Utilising these recombinant allergens Ara h 1-3, rAra h 8, a Bet v 1-homologous panallergen, as well as nsLTP (rPru p 3), will be of value in the assessment of peanut allergy.

In particular, rAra h2 is of value in the identification of the high risk of systemic reactions.

- A positive peanut specific IgE and a negative rAra h 2 indicates risk of peanut allergy with severe and/or local reactions.
- A positive peanut specific IgE and a positive rAra h 2 indicates a high risk of peanut allergy with systemic and severe reactions.

Visit www.labspec.co.za for more information and details of diagnostic products. LabSpec, PO Box 1259, Ferndale 2160. Tel +27 (0) 11-792-6790, +27 (0) 21-910-2736.

Phadia



PRODUCT NEWS



MSD (Pty) Ltd is proud to announce the introduction of SINGULAIR 4 mg. Studies have shown that asthma in children under the age of six is on the increase worldwide.¹ SINGULAIR 4 mg is the first asthma controller therapy, that is not a steroid, to be approved in South Africa for children as young as 2 years old.²

Studies have shown improvements in symptom and activity scores from as early as day one, affirming the efficacy of SINGULAIR 4 mg in this age group.³ The current guidelines for treatment of asthma in children, as compiled by the Allergy Society of South Africa (ALLSA), call for the introduction of a leukotriene antagonist as a controller agent in this age group at step 2, after the use of short-acting reliever medication has proven to be inadequate in controlling asthma symptoms. In other words using leukotriene antagonist as a first line controller agent.⁴ At present, of the leukotriene receptor antagonists, only SINGULAIR is indicated for use in children under the age of 12.²

SINGULAIR 4 mg is indicated for the prophylactic treatment of mild to moderate asthma in the 2-5 year old age group. SINGULAIR 4 mg is presented in a 28-day pack and one tablet should be taken once daily at bedtime.² To date worldwide use is more than 2.2 million children in more than 90 countries. This puts SINGULAIR in the unique position of being the only controller therapy to be registered and indicated for asthmatic patients from 2 years old and up.²




The **FREEDOM** to be a **Child!**

REFERENCES:

- 1 Ehrlich, R. The Prevalence of Asthma in South Africa. *Current Allergy and Clinical Immunology* March 2002; Vol 15: 4-8.
- 2 Data on File.
- 3 Knorr B, Franchi LM, Bisgaard H, *et al.* Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. *Pediatrics* 2001; **108**(3):1-10.
- 4 Motala C, Kling S, Gie R, *et al.* Guideline for the management of Chronic Asthma in Children – 2000 Update. *SAMJ.* 2000; **90**: 524-539.

MSD (Pty) Ltd (Reg. No. 1996/003791/07), Private Bag 3, Halfway House 1685.

Copyright © MERCK & CO., INC., Whitehouse Station, N.J., U.S.A. 1999. © Registered Trademark of MERCK & CO., INC., Whitehouse Station, N.J., U.S.A. Before prescribing, please refer to the full package insert. 06-2004-SGA-03-ZA-230-O

Reg. No: 35/10.2.2/0397, SINGULAIR 4 mg 



Foratec HFA

Foratec HFA is another exciting addition to Cipla's range of respiratory products, emphasising our commitment to offering solutions for Total Asthma Control!

Foratec HFA (formoterol fumarate 12µg) is:

- " a long-acting β_2 -agonist, giving up to 12 hours bronchodilation¹
- " as fast-acting as salbutamol,² between 1-3 minutes¹
- " the only available formoterol fumarate MDI
- " a 120-dose MDI; 2 months' supply (at 1 puff b.d.)
- " CFC-free, re-enforcing our global commitment to preserving our planet within our sphere of influence
- " indicated as add-on therapy to inhaled corticosteroids in patients with chronic persistent asthma (GINA step 3)³ and for prophylaxis and treatment of symptoms in patients with COPD¹,
- " priced at R69.60 SEP (excl VAT), the most cost-effective long-acting β_2 -agonist in SA!⁵



Isn't this enough reason to prescribe **Foratec HFA**?

Cipla offers you **Total Asthma Control through choice of molecules, choice of devices and a choice to treat cost-effectively!**

Prescribing information available on request. Please contact Elizma Kemp on 021-917-5620.

1. Foratec HFA Package Insert
2. Van Noord J, *et al.* Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. *Eur Respir J* 1996; **9**: 1684-1688
3. Asthma Guideline Implementation Project. Primary care management of adults with chronic asthma. Revised 2006. *SA Family Practice Journal.* June 2007; **49**: 19-31
4. Bateman ED, Feldman C, O'Brien J, Plit M, Joubert JR. Guideline for the management of chronic obstructive pulmonary disease (COPD): Revised 2004. *S Afr Med J.* 2004; **94**(7 Pt 2): 559-575.
5. SEP (excl. VAT) as per PCD, July 2008

PRODUCT NEWS

MIELE LAUNCHES TOP-CLASS RANGE OF VACUUM CLEANERS

A fact of modern life is the increase in allergies, with more and more adults and children suffering from asthma, rhinitis and hay fever. Allergies are made worse by household pets, and dust mites in carpets, mattresses and soft furnishings. In response to the growing need for appliances that can help alleviate the problems suffered by allergy sufferers Miele have developed a number of features and accessories to ensure excellent levels of cleanliness in the home.



The S5281 MedicAir Vacuum Cleaner is supplied with all the features and accessories to meet the specific needs of allergy sufferers. The unit is equipped with an innovation that offers additional security and comfort; the Allergotec Sensor floorhead for visible hygienic cleanliness.

Miele offers a choice of three filters placed behind the motor. Because of the airtight design, any air leaving the vacuum cleaner only leaves via the final filter. The **Miele Super AirClean filter** removes nearly 94% of the particles as small as 0.3 μ and, for this reason is the most suitable for everyday households. The **Miele Active AirClean filter** incorporates the Super AirClean filter and is designed for customers who have to vacuum up items with unpleasant odours. A tight-fitting filter cassette with a rubber seal prevents any air escaping. The active charcoal component absorbs and neutralises odours. The **Miele**

Active HEPA filter solves the problems of allergy sufferers. The Active HEPA filter retains 99.5% of particles.

For the true pet lover – the S5261 in Capri Blue and S5361 in Tayberry Red are Miele's Cat & Dog range of vacuum cleaners. Stubborn pet hairs do not stand a chance with the Miele Cat & Dog's Turbo Brush. This special floorhead is driven by the suction of the cleaner and rotates evenly to pick up hair and dirt from most types of carpets, while the smooth running floor head SBD takes care of most hard floor surfaces. The Miele Cat & Dog vacuum cleaner is specially fitted with an ActiveAirClean filter. The activated charcoal filling ensures any smell arising from the contents of the dustbag is absorbed before it leaves the cleaner and that the exhausted air is always fresh too.



Anything else is a compromise

Miele (Pty) Ltd Gallery of Fine Living (Head Office),
PO Box 69434, Bryanston, 2021,
ashley.merson@miele.co.za,
www.miele.co.za_info@miele.co.za
Share call: 0860 000 622,
Share fax: 0860 000 633.

BOEHRINGER INGELHEIM LAUNCHES INFLANAZE® 100.

It is with great pleasure and excitement that Boehringer Ingelheim, a leader in respiratory care, announces the launch of **Inflanaze® 100**.

Allergic rhinitis is a highly prevalent chronic respiratory disease that impacts significantly on the quality of life of patients.¹ The prevalence of allergic rhinitis is rising with a huge indirect and direct economic burden.¹ In addition nearly 80 % of asthmatic patients have coexisting allergic rhinitis.² Topical corticosteroids are highly effective first-line treatment of allergic rhinitis.³ Budesonide is comparatively an effective corticosteroid which is well tolerated for all classifications of allergic rhinitis.⁴

Inflanaze® 100, 100 μ g budesonide per metered spray, provides another option for healthcare professionals to treat this common respiratory disease. **Inflanaze® 100** provides high dose budesonide for the allergic rhinitis patient and allows tapering down of medication to the lowest dose adequate to control symptoms.⁵ With its less number of sprays per day, the new 100 dosage allows for better patient compliance.¹ It is registered from the age of 6 years allowing for use in children.

Inflanaze® 50 and 100 possess a broad actuator making the administration of medication to children and patients who struggle to use nasal sprays easy and comfortable.

Inflanaze® 100 contains 200 doses, contains no alcohol and has potassium sorbate as its preservative.⁶

This product addition shows that Boehringer Ingelheim, with its wide range of medication for asthma and allergic rhinitis, is committed to optimising respiratory care.



References:

1. Yawn B. Comparison of Once-Daily Intra-nasal Corticosteroids for the Treatment of Allergic Rhinitis: Are they all the same? *Medscape General Medicine* 2006; 8(1): 23.
2. Grossman J. One Airway, One Disease. *Chest* 1997; 111(2)(Suppl): 11S-16S.
3. Van Cauwenberge P. Consensus Statement on the Treatment of Allergic Rhinitis. *Allergy* 2000; 55: 116-134.
4. Stanaland B. Once-Daily Budesonide Aqueous Nasal Spray for Allergic Rhinitis: A Review. *Clinical Therapeutics* 2004; Vol.26(4): 473-492.
5. Inflanaze® 100 Package Insert.
6. Data on File

[S3] Inflanaze® 50 Aqueous Nasal Spray. Each metered dose contains 50 μ g budesonide. Reg. No 32/21.5.1/0532

[S3] Inflanaze® 100 Aqueous Nasal Spray. Each metered dose contains 100 μ g micronised budesonide. Reg. No. 41/21.5.1/0238

For full prescribing information refer to the package insert.

Applicant details: Ingelheim Pharmaceuticals (Pty) Ltd,
407 Pine Ave, Randburg. Tel: +27 (011) 348-2400.
Fax: +27 (011) 787-3766. Cpy Reg. No. 1966/008618/07.
BI Ref. No. 72/2009 (Mar 09).
NOPO



PRODUCT NEWS

MIELE LAUNCHES TOP-CLASS RANGE OF VACUUM CLEANERS

A fact of modern life is the increase in allergies, with more and more adults and children suffering from asthma, rhinitis and hay fever. Allergies are made worse by household pets, and dust mites in carpets, mattresses and soft furnishings. In response to the growing need for appliances that can help alleviate the problems suffered by allergy sufferers Miele have developed a number of features and accessories to ensure excellent levels of cleanliness in the home.



The S5281 MedicAir Vacuum Cleaner is supplied with all the features and accessories to meet the specific needs of allergy sufferers. The unit is equipped with an innovation that offers additional security and comfort; the Allergotec Sensor floorhead for visible hygienic cleanliness.

Miele offers a choice of three filters placed behind the motor. Because of the airtight design, any air leaving the vacuum cleaner only leaves via the final filter. The **Miele Super AirClean filter** removes nearly 94% of the particles as small as 0.3 μ and, for this reason is the most suitable for everyday households. The **Miele Active AirClean filter** incorporates the Super AirClean filter and is designed for customers who have to vacuum up items with unpleasant odours. A tight-fitting filter cassette with a rubber seal prevents any air escaping. The active charcoal component absorbs and neutralises odours. The **Miele**

Active HEPA filter solves the problems of allergy sufferers. The Active HEPA filter retains 99.5% of particles.

For the true pet lover – the S5261 in Capri Blue and S5361 in Tayberry Red are Miele's Cat & Dog range of vacuum cleaners. Stubborn pet hairs do not stand a chance with the Miele Cat & Dog's Turbo Brush. This special floorhead is driven by the suction of the cleaner and rotates evenly to pick up hair and dirt from most types of carpets, while the smooth running floor head SBD takes care of most hard floor surfaces. The Miele Cat & Dog vacuum cleaner is specially fitted with an ActiveAirClean filter. The activated charcoal filling ensures any smell arising from the contents of the dustbag is absorbed before it leaves the cleaner and that the exhausted air is always fresh too.



Anything else is a compromise

Miele (Pty) Ltd Gallery of Fine Living (Head Office),
PO Box 69434, Bryanston, 2021,
ashley.merson@miele.co.za,
www.miele.co.za, info@miele.co.za
Share call: 0860 000 622,
Share fax: 0860 000 633.

BOEHRINGER INGELHEIM LAUNCHES INFLANAZE® 100 μ g.

It is with great pleasure and excitement that Boehringer Ingelheim, a leader in respiratory care, announces the launch of **Inflanaze® 100 μ g.**

Allergic rhinitis is a highly prevalent chronic respiratory disease that impacts significantly on the quality of life of patients.¹ The prevalence of allergic rhinitis is rising with a huge indirect and direct economic burden.¹ In addition nearly 80% of asthmatic patients have coexisting allergic rhinitis.² Topical corticosteroids are highly effective first-line treatment of allergic rhinitis.³ Budesonide is comparatively an effective corticosteroid which is well tolerated for all classifications of allergic rhinitis. In addition, it is considered cost effective when compared to other intranasal corticosteroids.⁴

Inflanaze® 100 μ g provides another option for healthcare professionals to treat this common respiratory disease.

Inflanaze® 100 μ g provides high dose budesonide for the allergic rhinitis patient and allows tapering down of medication to the lowest dose adequate to control symptoms.⁵ With its less number of sprays per day, the new 100 μ g dosage allows for better patient compliance.¹ It is registered from the age of 6 years allowing for use in children. Budesonide has been shown to have no significant side effects in children.¹

Inflanaze® 50 μ g and **100 μ g** possess a broad actuator making the administration of medication to children and patients who struggle to use nasal sprays easy and comfortable.

Inflanaze® 100 μ g contains 200 doses which, when compared to other 100 μ g nasal sprays, makes it very affordable.⁶



This product addition shows that Boehringer Ingelheim, with its wide range of medication for asthma and allergic rhinitis, is committed to optimising respiratory care.

1. Yawn B. Comparison of Once-Daily Intranasal Corticosteroids for the Treatment of Allergic Rhinitis: Are they all the same? *Medscape General Medicine* 2006; 8(1):23.
2. Grossman J. One Airway, One Disease. *Chest* 1997; 111(2)(Suppl): 11S-16S.
3. Van Cauwenberge P. Consensus Statement on the Treatment of Allergic Rhinitis. *Allergy* 2000;55: 116-134.
4. Stanaland B. Once-Daily Budesonide Aqueous Nasal Spray for Allergic Rhinitis: A Review. *Clinical Therapeutics* 2004; Vol.26(4): 473-492.
5. Inflanaze® 100 Package Insert.
6. Data on File

[S3] Inflanaze® 50 Aqueous Nasal Spray. Each metered dose contains 50 μ g budesonide. Reg. No 32/21.5.1/0532

[S3] Inflanaze 100 Aqueous Nasal Spray. Each metered dose contains 100 μ g micronised budesonide. Reg. No. 41/21.5.1/0238

For full prescribing information refer to the package insert. Applicant details: Ingelheim Pharmaceuticals (Pty) Ltd, 407 Pine Ave, Randburg. Tel: +27 (011) 348-2400. Fax: +27 (011) 787-3766. Cpy Reg. No. 1966/008618/07. BI Ref. No. 72/2009(Mar 09).

NOPO



